SG Tylor
Boehringer Launches Pivotal Trial for Liposarcoma Drug
Boehringer Ingelheim has initiated a registration trial for its investigational therapy, brigimadlin, as a potential treatment for dedifferentiated liposarcoma (DDLPS), ...
Ovarian Cancer: Upifitamab Rilsodotin Misses Primary End Point
Source – Mersana Therapeutics According to Mersana Therapeutics, the antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) did not achieve its ...
How EQRxâs Cheap Drugs Strategy Led to Revolution Deal
Source – Revolution Medicines EQRx, which made a bold claim to disrupt the pharmaceutical pricing system in 2020, has now ...
As COVID revenues fall short of expectations, once-flying Pfizer considers cost-cutting measures
As the revenues from COVID-19 products fluctuate, mostly experiencing a decline, Pfizer is now considering implementing cost-cutting measures. During a ...
Manufacturer SterRx closes its New York facility and fires 161 workers
SterRx, a manufacturer based in New York, has closed its Plattsburgh plant and terminated 161 employees as a result. The ...
Boehringer Ingelheim Soars with Jardiance Growth as US Kidney Disease Approval Looms
Source – Boehringer Ingelheim Boehringer Ingelheim is gearing up for the launch of Jardiance, a diabetes and heart failure drug, ...
First-ever JUVĂDERM Day is announced by Allergan Aesthetics
Source – Abbvie That sounds like an exciting announcement! Allergan Aesthetics, now an AbbVie company, is celebrating the first-ever JUVĂDERM ...
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
TheracosBio’s Bold Move: New CEO Takes Charge After FDA Approval and Price Showdown with Diabetes Drug Brenzavvy
TheracosBio, after securing its first-ever FDA approval for the SGLT2 diabetes drug Brenzavvy, has undergone a CEO change, with Brian ...
TG Therapeutics Partners with Neuraxpharm to Launch Game-Changing Multiple Sclerosis Antibody Briumvi Worldwide
After gaining approval for Briumvi in the US eight months ago, TG Therapeutics is now set to introduce its multiple ...
Blockbuster Cancer Immunotherapy Showdown Ends: Bristol Myers Squibb and AstraZeneca Settle Patents Clash
Bristol Myers Squibb (BMS) and AstraZeneca have quickly resolved patent infringement lawsuits related to their cancer immunotherapies. The companies reached ...
Endometrial Cancer: Symptoms, Risks, and Treatments
Endometrial cancer is the most common type of uterine cancer. Find out what causes it, how to spot the warning ...
Trodelvy: The New Hope for Breast Cancer Patients
Trodelvy is a brand name for sacituzumab govitecan-hziy, a new type of drug that combines an antibody with a chemotherapy ...
The VOYAGER Trial Illustrates the Potential of ctDNA in GIST
ctDNA analysis is a valuable tool in monitoring disease progression and tailoring treatments for patients with gastrointestinal stromal tumor (GIST), ...
Beginning of TNG260 and Pembrolizumab Study in Advanced Solid Tumors
The first patient has received a dose of TNG260 in combination with pembrolizumab (Keytruda) as part of a Phase I/II ...
FDA rejects Citius’ resurrected IL-2 lymphoma treatment
Source – Citius Pharmaceuticals The FDA has declined Citius Pharmaceuticals’ request to market Lymphir, an updated version of a lymphoma ...
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced nonâsmall cell lung cancer ...
Enhertu in Breast Cancer: A Breakthrough Treatment for HER2-Positive and HER2-Low
This blog post will review how Enhertu in breast cancer works, how it is used, its benefits and risks, how ...
AstraZeneca Expects Higher China Sales, Denies Spinoff Report
AstraZenecaâs CEO Pascal Soriot has denied a report that the company is considering spinning off its China business, which is ...
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
Teva Aims for Growth by 2027 After $4.25B Opioid Settlement
Teva Pharmaceutical is shifting its focus back to its core businesses in generics and biosimilars, seeing promising opportunities in both ...
Roche Halts Development of Tenecteplase for Stroke
Roche announced today that it has discontinued the development of its thrombolytic drug tenecteplase for acute ischemic stroke due to ...
Enhertu increases survival in solid tumors with HER2+
AstraZeneca and Daiichi Sankyo have received a boost in their efforts to gain approval for Enhertu as a therapy for ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Lundbeck and Otsuka Collaborate to Raise Awareness of Alzheimer’s Agitation Treatment
Lundbeck and Otsuka have intensified their efforts to address a niche area in Alzheimer’s disease treatment. Following their FDA approval ...
Vabysmo, Roche’s Top Eye Medicine, Crosses Blockbuster Threshold Ahead of Competitors
According to Roche’s pharma chief, Teresa Graham, their eye drug Vabysmo is currently experiencing significant momentum. Since its FDA approval ...
Gilead’s Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer Receives European Commission Approval
Source – Gilead Gilead Sciences, has received approval from the European Commission (EC) for the use of Trodelvy (sacituzumab govitecan) ...
Teva Seeks Appeal in Kickbacks Case Amid $10 Billion Trial Risk
Teva has been grappling with opioid litigation for several years, culminating in a multibillion-dollar settlement last year. However, the company ...
Qunol, a rapidly expanding US brand in the healthy aging market, will be acquired by Sanofi
Source – Sanofi Paris, July 28, 2023. Sanofi announces its strategic move to acquire Qunol, a renowned and leading brand ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
